Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

Jeffrey Szer, MBBS, Petra Muus, MD, PhD, Alexander Roeth, MD, M.O Elebute, MD, FRCP, FRCPath, Antonio M. Risitano, MD, PhD, Hubert Schrezenmeier, MD, Jaroslaw P. Maciejewski, MD, PhD, Alvaro Urbano-Ispizua, MD, Carlos Manuel de Castro, III, MD, Gérard Socié, MD PhD, Robert A. Brodsky, MD

Blood (2012) 120 (21): 1260.

https://doi.org/10.1182/blood.V120.21.1260.1260

Published: 2012

Journal Articles

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Anne W Beaven, MD, David A. Rizzieri, MD, Zachary Powell, Zhiguo Li, PhD, Peggy Alton, RN, Julie Warzecho, RN, Louis F. Diehl, MD, Joseph O. Moore, MD, Carlos Manuel de Castro, III, MD, Jon P. Gockerman, MD

Blood (2011) 118 (21): 2681.

https://doi.org/10.1182/blood.V118.21.2681.2681

Published: 2011

Journal Articles

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Arati V Rao, MD, David A. Rizzieri, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Mitchell E. Horwitz, MD, Joseph O. Moore, MD, Natalie Sacarakis, Carlos Manuel de Castro, III, MD

Blood (2011) 118 (21): 5021.

https://doi.org/10.1182/blood.V118.21.5021.5021

Published: 2011

Journal Articles

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Carlos Manuel de Castro, III, MD, Donna Adams, RN, Arati V Rao, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Julie Warzecho, RN, David A. Rizzieri, MD

Blood (2011) 118 (21): 5029.

https://doi.org/10.1182/blood.V118.21.5029.5029

Published: 2011

Journal Articles

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Mulitple Myeloma

Lauren Held, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos Manuel de Castro, III, MD, Joseph O. Moore, MD, David A. Rizzieri, MD, Gwynn D. Long, MD, Mitchell E. Horwitz, MD, Nelson J. Chao, MD, Cristina Gasparetto, MD

Blood (2011) 118 (21): 5129.

https://doi.org/10.1182/blood.V118.21.5129.5129

Published: 2011

NARROW

Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Mulitple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Mulitple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only